CDXS
Codexis, Inc. NASDAQ Listed Apr 22, 2010$2.59
After hrs
$2.82
-1.00%
Mkt Cap $235.4M
52w Low $0.96
56.0% of range
52w High $3.87
50d MA $1.92
200d MA $2.07
P/E (TTM)
-5.3x
EV/EBITDA
-5.5x
P/B
4.6x
Debt/Equity
1.4x
ROE
-87.0%
P/FCF
-6.0x
RSI (14)
—
ATR (14)
—
Beta
2.08
50d MA
$1.92
200d MA
$2.07
Avg Volume
2.4M
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
200 Penobscot Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11, 2026 | AMC | 0.01 | 0.11 | +1000.0% | 1.27 | +52.0% | +34.6% | +26.8% | +18.1% | +15.7% | +15.7% | — |
| Nov 6, 2025 | AMC | -0.15 | -0.22 | -46.7% | 2.04 | -19.6% | -17.2% | -14.2% | -11.8% | -5.4% | -20.1% | — |
| Aug 13, 2025 | AMC | -0.17 | -0.16 | +5.9% | 3.05 | +11.5% | +1.6% | -1.3% | -1.6% | -5.9% | -7.5% | — |
| May 14, 2025 | AMC | -0.20 | -0.25 | -25.0% | 2.47 | -9.7% | +1.6% | +0.0% | -1.6% | -0.8% | -5.3% | — |
| Feb 27, 2025 | AMC | -0.04 | -0.13 | -225.0% | 3.93 | -10.9% | -22.6% | -30.3% | -31.8% | -30.5% | -30.5% | — |
| Oct 31, 2024 | AMC | -0.25 | -0.29 | -16.0% | 3.14 | +5.7% | +11.5% | +11.1% | +21.7% | +27.7% | +33.1% | — |
| Aug 8, 2024 | AMC | -0.26 | -0.32 | -23.1% | 3.15 | -2.2% | -11.1% | -10.5% | -11.1% | -10.5% | -10.8% | — |
| May 2, 2024 | AMC | -0.17 | -0.16 | +5.9% | 3.34 | +8.4% | +17.4% | +6.6% | +5.7% | +3.6% | +3.9% | — |
| Feb 28, 2024 | AMC | -0.16 | 0.02 | +112.5% | 3.72 | +5.6% | +25.0% | +23.9% | +13.2% | +1.1% | -2.2% | — |
| Nov 2, 2023 | AMC | -0.32 | -0.26 | +18.8% | 1.80 | +7.2% | +7.2% | -3.1% | -3.3% | -9.4% | -11.1% | — |
| Aug 3, 2023 | AMC | -0.21 | -0.17 | +19.0% | 3.38 | +4.7% | -14.5% | -26.3% | -32.2% | -35.2% | -37.0% | — |
| May 4, 2023 | AMC | -0.29 | -0.34 | -17.2% | 3.95 | -2.3% | -4.8% | -13.7% | -21.8% | -27.6% | -33.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $4.33 | $4.37 | +0.9% | +6.5% | +5.1% | +5.3% | +6.0% | +5.8% |
| Nov 15 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.74 | $3.80 | +1.6% | +3.7% | +5.1% | +13.6% | +15.8% | +15.8% |
| Sep 20 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.21 | $3.19 | -0.6% | -3.4% | -9.0% | -10.0% | -9.3% | -3.4% |
| Aug 29 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.91 | $2.95 | +1.4% | -0.3% | -0.7% | -2.1% | -2.7% | -3.4% |
| Aug 19 | Benchmark | Downgrade | Buy → Hold | — | $2.91 | $2.78 | -4.5% | +3.4% | +2.1% | +3.1% | -0.3% | +4.8% |
| Aug 9 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $3.15 | $3.08 | -2.2% | -11.1% | -10.5% | -11.1% | -10.5% | -10.8% |
| May 3 | Benchmark | Maintains | Buy → Buy | — | $3.34 | $3.62 | +8.4% | +17.4% | +6.6% | +5.7% | +3.6% | +3.9% |
| Feb 29 | Benchmark | Upgrade | Hold → Buy | — | $3.72 | $3.93 | +5.6% | +25.0% | +23.9% | +13.2% | +1.1% | -2.2% |
| Nov 7 | Benchmark | Downgrade | Buy → Hold | — | $1.75 | $1.69 | -3.2% | -0.3% | -6.6% | -8.3% | -4.9% | -4.9% |
| Nov 6 | Piper Sandler | Maintains | Overweight → Overweight | — | $1.93 | $1.93 | +0.0% | -9.6% | -9.8% | -15.5% | -17.1% | -14.0% |
| Sep 1 | Benchmark | Maintains | Buy → Buy | — | $1.74 | $1.76 | +1.1% | +3.4% | +3.4% | -3.4% | -7.5% | -1.1% |
| Aug 14 | Stifel | Maintains | Buy → Buy | — | $2.09 | $2.05 | -1.9% | -5.7% | -12.0% | -18.2% | -19.1% | -20.6% |
| Jul 21 | Stephens & Co. | Maintains | Overweight → Overweight | — | $3.47 | $3.54 | +2.0% | +8.1% | +3.7% | -0.9% | +1.4% | +0.0% |
| May 9 | Benchmark | Maintains | Buy → Buy | — | $3.41 | $3.13 | -8.2% | -9.4% | -16.1% | -22.6% | -22.3% | -19.1% |
| May 9 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $3.41 | $3.13 | -8.2% | -9.4% | -16.1% | -22.6% | -22.3% | -19.1% |
| Apr 17 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.10 | $4.09 | -0.2% | +5.9% | +1.5% | +3.4% | +0.0% | +4.9% |
| Feb 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.73 | $4.86 | +2.7% | -2.1% | +2.3% | -2.1% | +0.8% | +4.2% |
| Jan 19 | Piper Sandler | Maintains | Overweight → Overweight | — | $5.96 | $5.86 | -1.7% | +1.8% | +9.2% | +13.4% | +6.5% | +10.9% |
| Nov 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.34 | $6.22 | -1.9% | -8.0% | -4.9% | -10.3% | +5.7% | +7.9% |
| Aug 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.75 | $8.72 | -0.3% | -5.5% | -11.1% | -0.6% | -4.7% | +1.0% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.67 | $6.98 | +4.6% | +2.1% | +7.0% | +17.5% | +21.4% | +11.8% |
| Jul 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.07 | $8.47 | -29.8% | -44.7% | -43.6% | -40.8% | -35.0% | -32.9% |
| Jul 15 | Cowen & Co. | Maintains | Outperform → Outperform | — | $12.07 | $8.47 | -29.8% | -44.7% | -43.6% | -40.8% | -35.0% | -32.9% |
| May 11 | Stephens & Co. | Maintains | Overweight → Overweight | — | $10.60 | $10.38 | -2.1% | -8.5% | -0.3% | +3.5% | -4.0% | +1.4% |
| Nov 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $34.96 | $40.00 | +14.4% | +14.9% | +19.5% | +14.8% | +9.6% | +7.4% |
| Oct 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $27.48 | $27.83 | +1.3% | +3.1% | +1.1% | +8.2% | +6.5% | +4.6% |
| Aug 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.65 | $23.84 | +5.3% | +11.8% | +15.5% | +13.1% | +12.0% | +7.0% |
| Jun 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $19.64 | $20.09 | +2.3% | +12.6% | +8.2% | +6.6% | +8.6% | +13.7% |
| Apr 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $24.00 | $24.73 | +3.0% | -2.2% | +0.8% | +2.2% | +2.3% | -1.7% |
| Mar 1 | Stifel | Maintains | Buy → Buy | — | $22.11 | $23.07 | +4.3% | +6.2% | +2.2% | -5.7% | -9.5% | -11.8% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $21.24 | $22.15 | +4.3% | +4.1% | +10.5% | +6.4% | -1.8% | -5.8% |
| May 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.23 | $11.98 | -2.0% | -2.2% | -5.1% | -8.5% | -12.0% | -9.2% |
| Jan 17 | First Analysis | Upgrade | Neutral → Outperform | — | $16.40 | $16.88 | +2.9% | +6.0% | +3.7% | +0.4% | +2.3% | +3.3% |
| Jun 19 | Cowen & Co. | Maintains | Outperform → Outperform | — | $15.45 | $15.50 | +0.3% | +1.6% | +6.5% | +2.3% | +2.6% | -6.5% |
| Oct 13 | Jefferies | Maintains | Buy → Buy | — | $7.85 | $7.95 | +1.3% | -4.5% | -2.5% | -6.4% | -7.0% | -7.3% |
| May 31 | Jefferies | Maintains | Buy → Buy | — | $4.30 | $4.40 | +2.3% | -7.0% | -7.0% | +3.5% | +3.5% | +5.8% |
| Jan 26 | First Analysis | Downgrade | Overweight → Equal Weight | — | $5.05 | $4.90 | -3.0% | -2.0% | -4.0% | -6.9% | -5.9% | -7.9% |
| Jan 4 | Ladenburg Thalmann | Upgrade | Neutral → Buy | — | $4.50 | $4.80 | +6.7% | +5.6% | +2.2% | +5.6% | +10.0% | +12.2% |
| Jan 6 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.23 | $4.22 | -0.2% | +0.0% | -2.4% | -1.4% | +3.8% | +1.2% |
| Mar 4 | Ladenburg Thalmann | Downgrade | Buy → Neutral | — | $3.78 | $3.78 | +0.0% | +3.2% | +5.6% | -2.1% | -1.3% | -2.9% |
| Apr 9 | Sidoti & Co. | Maintains | Neutral → Neutral | — | $2.10 | $2.10 | +0.0% | -1.0% | +5.7% | +7.6% | +8.1% | -1.9% |
| Sep 5 | Piper Sandler | Upgrade | Underweight → Neutral | — | $2.20 | $2.47 | +12.3% | +3.6% | +10.9% | +20.9% | +23.6% | +28.6% |
| Sep 5 | PiperJaffray | Upgrade | Underweight → Neutral | — | $2.20 | $2.47 | +12.3% | +3.6% | +10.9% | +20.9% | +23.6% | +28.6% |
| Aug 10 | Piper Sandler | Maintains | Underweight → Underweight | — | $3.10 | $2.94 | -5.2% | -21.3% | -25.2% | -21.0% | -25.5% | -25.5% |
| Aug 10 | PiperJaffray | Maintains | Underweight → Underweight | — | $3.10 | $2.94 | -5.2% | -21.3% | -25.2% | -21.0% | -25.5% | -25.5% |
| Aug 10 | Credit Suisse | Downgrade | Outperform → Neutral | — | $3.10 | $2.94 | -5.2% | -21.3% | -25.2% | -21.0% | -25.5% | -25.5% |
| May 11 | Piper Sandler | Maintains | Underweight → Underweight | — | $3.36 | $3.31 | -1.5% | -2.4% | -6.8% | -6.2% | -4.8% | -4.8% |
| May 11 | PiperJaffray | Maintains | Underweight → Underweight | — | $3.36 | $3.31 | -1.5% | -2.4% | -6.8% | -6.2% | -4.8% | -4.8% |
| Feb 21 | PiperJaffray | Maintains | Underweight → Underweight | — | $4.58 | $4.30 | -6.1% | -19.2% | -15.3% | -13.1% | -13.1% | -14.6% |
| Feb 21 | Piper Sandler | Downgrade | Neutral → Underweight | — | $4.58 | $4.30 | -6.1% | -19.2% | -15.3% | -13.1% | -13.1% | -14.6% |
No insider trades available.
8-K
Unknown — 8-K Filing
Dr. Martinborough's board reclassification is purely administrative, preserving committee continuity and avoiding disruption to governance—investors should note no material leadership changes occurred.
Apr 14
8-K
Unknown — 8-K Filing
Codexis secured a $37.8M Merck deal and has 2027 cash runway, but full-year revenue of only $70.4M suggests slow growth; investors should monitor whether partnerships can drive profitability before cash depletion.
Mar 11
Data updated apr 25, 2026 12:36am
· Source: massive.com